Pavic, Karolina

Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56

Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports

Cancer Mechanisms and TherapySignaling Pathways in Disease

Cited by 95

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 65

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · Cancer Research

DNA Repair MechanismsBreast Cancer Treatment Studies

Cited by 54

Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A

Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., et al. (2023) · Nature Communications

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 36

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Mäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsRNA Research and Splicing

Cited by 18